NYSE: JNJJohnson & Johnson Stock
$169.98+0.49 (0.29%)
Updated Jul 22, 2021
JNJ Price
$169.98
Fair Value Price
N/A
Market Cap
$447.62B
52 Week Low
$133.65
52 Week High
$173.65
P/E
29.61x
P/B
6.8x
P/S
5.09x
PEG
1.21x
Dividend Yield
2.41%
Revenue
$84.21B
Earnings
$15.12B
Gross Margin
66.2%
Operating Margin
20.97%
Profit Margin
17.9%
Debt to Equity
1.62
Operating Cash Flow
$24B
Beta
0.66
Next Earnings
N/A
Ex-Dividend
Aug 23, 2021
Next Dividend
Sep 7, 2021
Zen Score
High
Medium
Low
48
Industry average
Reasons for this score
JNJ ($169.98) is trading below its intrinsic value of $536.25, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
JNJ is poor value based on its earnings relative to its share price (29.61x), compared to the US market average (28.43x)
Valuation
JNJ is good value based on its earnings relative to its share price (29.61x), compared to the US Drug Manufacturers - General industry average (33.42x)
Valuation
JNJ News
Valuation
JNJ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.61x
Industry
33.42x
Market
28.43x
JNJ is poor value based on its earnings relative to its share price (29.61x), compared to the US market average (28.43x)
Valuation
JNJ is good value based on its earnings relative to its share price (29.61x), compared to the US Drug Manufacturers - General industry average (33.42x)
Valuation
JNJ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.8x
Industry
5.4x
JNJ is poor value based on its book value relative to its share price (6.8x), compared to the US Drug Manufacturers - General industry average (5.4x)
Valuation
JNJ price to earnings growth (PEG)
For valuing profitable companies with growth potential
JNJ is poor value relative to its rate of earnings growth, measured by PEG ratio (1.21x)
Valuation
JNJ's financial health
Profit margin
Revenue
$22.3B
Net Income
$6.2B
Profit Margin
27.8%
JNJ's Earnings (EBIT) of $17.66B can safely cover interest payments on company debt ($33.61B)
Financials
JNJ's profit margin has decreased (-2.8%) in the last year from (20.7%) to (17.9%)
Financials
Assets to liabilities
Assets
$172.6B
Liabilities
$106.7B
Debt to equity
0.51
JNJ's short-term assets ($52.53B) exceed its short-term liabilities ($40.93B)
Financials
JNJ's long-term liabilities ($65.79B) exceed its short-term assets ($52.53B)
Financials
JNJ's debt has increased relative to shareholder equity (1.62), over the past 5 years ago (0.88)
Financials
JNJ's debt to equity ratio (1.62) is considered high
Financials
Cash flow
Operating
$4.1B
Investing
-$185.0M
Financing
-$5.1B
JNJ's operating cash flow ($24.25B) is sufficient to service the company's debt ($33.61B)
Financials
Johnson & Johnson Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.